Liang Zhao, Zongjian Liu, Chunlai Pan, Lihua Wang, Hexue Yuan
Department of Colorectal Anal Surgery, Shenyang Coloproctology Hospital, Shenyang, Liaoning, China.
Department of Pathology, Shenyang Coloproctology Hospital, Shenyang, Liaoning, China.
Front Oncol. 2025 Jun 26;15:1535376. doi: 10.3389/fonc.2025.1535376. eCollection 2025.
The purpose of this case report is to explore the efficacy of comprehensive treatment of anal melanoma and to provide reference for the treatment of anal melanoma.
A rare case of anorectal melanoma was collected. After local excision, the patient was treated with a combination of the anti-vascular survival drug bevacizumab, anti-PD-1 immunotherapy and other treatments, and the patient's prognosis and survival were observed.
A 61-year-old male was admitted to the hospital with complaints of anal prolapse and a mass appearing after defecation, accompanied by intermittent bloody stool for one week. He was initially diagnosed with mixed hemorrhoids, and a hemorrhoidectomy was performed. Postoperative pathology confirmed malignant melanoma with negative surgical margins, leading to a clinical diagnosis of AM. Following local excision surgery, the patient underwent targeted therapy with bevacizumab, anti-PD-1 immunotherapy and other treatments. After nearly three years of follow-up, the patient remained in good condition and while follow-up CT and MRI revealed some enlarged lymph nodes, there were no symptoms or signs of systemic metastasis.
The combination of local resection of the primary lesion with bevacizumab targeted therapy and anti-PD-1 immunotherapy is feasible and can substantially improve the survival time of patients with AM.
本病例报告旨在探讨肛管黑色素瘤综合治疗的疗效，为肛管黑色素瘤的治疗提供参考。
收集1例罕见的肛管直肠黑色素瘤病例。局部切除术后，患者接受抗血管生存药物贝伐单抗、抗程序性死亡蛋白1（PD-1）免疫治疗及其他治疗联合应用，并观察患者的预后及生存情况。
1例61岁男性因排便后肛门脱出伴肿物，伴间断便血1周入院。初诊为混合痔，行痔切除术。术后病理确诊为恶性黑色素瘤，手术切缘阴性，临床诊断为肛管黑色素瘤。局部切除术后，患者接受了贝伐单抗靶向治疗、抗PD-1免疫治疗及其他治疗。经过近3年的随访，患者情况良好，随访的CT和MRI显示有一些肿大淋巴结，但无全身转移的症状或体征。
原发灶局部切除联合贝伐单抗靶向治疗及抗PD-1免疫治疗可行，可显著提高肛管黑色素瘤患者的生存时间。
